Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
|Articles|October 7, 2015
Worldwide Medtech Sales Forecast to Reach $477.5 Billion by 2020
October 07, 2015.
Advertisement
The value of the global medtech market is expected to reach $477.5 billion by 2020, according life sciences market intelligence firm Evaluate Ltd. The “EvaluateMedTech World Preview 2015, Outlook to 2020” also states that worldwide medtech R&D expenditure is forecast to grow by 3.5 percent per annum to reach $29.5 billion by 2020. Other findings from the 2015 report:
- Worldwide medtech market forecast to grow more slowly than prescription drug market, with a CAGR of 4.1 percent between 2014 and 2020 versus 4.9 percent for pharma.
- Total medtech M&A deal values rose 166 percent to $84 billion in H1 2015.
- Medtronic’s $49.9 billion acquisition of Covidien in January 2015 was the biggest deal in medtech history.
- Johnson & Johnson held on to number one position in 2014 with medtech sales of $27.5 billion but Medtronic steals the top spot from 2015 onwards with a 2020 sales forecast of $34.9 billion.
The report can be downloaded at
http://www.evaluategroup.com/MedtechWP2015
.
Advertisement
Related to this article
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
The top barrier to AI adoption among pharma commercial leaders is compliance uncertainty, and the fix may be governance that evaluates one use case at a time.
Brox.AI’s Hamish Brocklebank on the three approaches to digital twins in pharma — and why only one-to-one clones of real individuals deliver true accuracy.
Pathos AI launches multi-year collaborations to build an AI-driven dataset for Alzheimer’s and other neurological diseases.
Advertisement
Advertisement
Trending on PharmExec
1
ANI Pharmaceuticals to Acquire Egetis Therapeutics, Egetis Sells Priority Review Voucher for $190 Million
2
Why Leronlimab Isn’t Just Another Repurposed Drug: Q&A with Dr. Jay Lalezari
3
Pharmaceutical Executive Daily: Nxera Licenses EP4 Agonist to AbbVie
4
What Does a Positive Reading for Leronlimab Mean for How the Industry Thinks About Repurposing Old Biologics Into Oncology?
5